<DOC>
	<DOCNO>NCT02574910</DOCNO>
	<brief_summary>Children congenital adrenal hyperplasia ( CAH ) due 21-hydroxylase deficiency tend elevate circulating level androgen , accelerate skeletal maturation adversely impact adult height . Additionally , child require supraphysiologic dos hydrocortisone suppress secretion adrenal androgen precursor , treatment retard linear growth . This study seek use oral abiraterone acetate ( Zytiga ) adjunct approve CAH therapy ( oral hydrocortisone fludrocortisone ) pre-pubescent child classic 21-hydroxylase deficiency order reduce daily requirement hydrocortisone . In Phase 1 study , investigator determine minimum effective dose abiraterone acetate normalize androstenedione level 7-day Treatment Period .</brief_summary>
	<brief_title>Androgen Reduction Congenital Adrenal Hyperplasia , Phase 1</brief_title>
	<detailed_description>Congenital adrenal hyperplasia ( CAH ) inherit inability synthesize cortisol adrenal gland . More 90 % case cause deficiency steroid 21-hydroxylase ( CYP21 , also term CYP21A2 , P450c21 ) , cytochrome P450 enzyme locate endoplasmic reticulum . It catalyze conversion 17-hydroxyprogesterone ( 17-OHP ) 11-deoxycortisol , precursor cortisol , progesterone deoxycorticosterone , precursor aldosterone . Aldosterone deficiency may lead salt waste consequent failure thrive , hypovolemia , shock untreated , death first week life . Because patient synthesize cortisol efficiently , adrenal cortex stimulate corticotropin ( ACTH ) overproduce cortisol precursor . Some precursor divert sex hormone biosynthesis , may cause sign androgen excess include ambiguous genitalia newborn female , rapid postnatal growth sex , accelerate skeletal maturation decrease adult height . Patients require supraphysiologic replacement dos glucocorticoid suppress adrenocorticotropic hormone ( ACTH ) -driven adrenal androgen synthesis . Excessive glucocorticoid associate excessive weight gain slow linear growth . It would desirable pre-pubertal child decrease exposure excess glucocorticoid avoid adverse effect inappropriate exposure androgen . Abiraterone acetate prodrug abiraterone , irreversible inhibitor 17α hydroxylase/C17 , 20-lyase ( cytochrome P450c17 [ CYP17 ] ) , key enzyme require testosterone synthesis . This agent indeed suppress adrenal androgen secretion adult woman . In Phase 1 study , investigator determine minimum effective dose abiraterone acetate normalize androstenedione level 7-day Treatment Period .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Adrenal Hyperplasia , Congenital</mesh_term>
	<mesh_term>Adrenogenital Syndrome</mesh_term>
	<mesh_term>Adrenocortical Hyperfunction</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>1 . Prepubescent girl ( age 2 year [ 12 kg minimum ] 8 year inclusive ; skeletal age ≤9 year ) boys ( age 2 year [ 12 kg ] 9 year inclusive ; skeletal age ≤10 year ) . 2 . Confirmed classic 21hydroxylase deficiency evident genotype clinical course ( e.g. , adrenal crisis document hyperkalemia hyponatremia , diagnosis later evaluation ; ambiguous genitalia female ) . 3 . Requirement standard care fludrocortisone ( dose ) ≥10 mg/m2/day hydrocortisone least 1 month prior study consent . 4 . Morning serum androstenedione concentration &gt; 1.5 x ULN 7 day dose dos hydrocortisone require physiologic replacement . 5 . A parent ( legally acceptable representative ) must sign informed consent 1 . Evidence central puberty : Tanner Stage &gt; 2 breast development girl testicular volume &gt; 4 mL boy , random LH &gt; 0.3 mIU/mL . Subjects pubic and/or axillary hair sign puberty onset allow . 2 . Current history hepatitis etiology , include history active viral hepatitis A , B , C. 3 . Abnormal liver function test , define AST , ALT bilirubin &gt; 3X ULN . 4 . Abnormal renal function test , define BUN creatinine &gt; 1.5 ULN age . 5 . Significant anemia ( hemoglobin &lt; 12 g/dl ) . 6 . Clinically significant abnormality 12lead electrocardiogram ( ECG ) 7 . A history malabsorption syndrome . 8 . Evidence active malignancy . 9 . Serious uncontrolled coexistent disease , include active uncontrolled infection . Subjects may rescreened resolution condition . 10 . Concurrent medical condition disease 21hydroxylase deficiency may interfere linear growth require concomitant therapy likely interfere study procedure result . 11 . Asthma require treatment systemic corticosteroid . Asthma treatment inhale corticosteroid permit . 12 . Treatment potentially hepatotoxic medication ( statin ) ; CYP2D6 substrates ( dextromethorphan , thioridazine ) , strong inhibitor CYP3A4 ( ketoconazole , itraconazole , clarithromycin , atazanavir , nefazodone , saquinavir , telithromycin , ritonavir , indinavir , nelfinavir , voriconazole ) , CYP3A4 inducer ( e.g. , phenytoin , carbamazepine , rifampin , rifabutin , rifapentine , phenobarbital ) . 13 . Treatment medication affect puberty synthesis sex steroid , include gonadotropin release hormone agonist , aromatase inhibitor , androgen receptor blocker ( e.g. , flutamide , spironolactone ) . However , gonadotropin release hormone agonist may start study treatmentemergent central puberty without disqualify subject 14 . Treatment growth hormone enrollment course study . 15 . Known allergy , hypersensitivity , intolerance abiraterone acetate excipients 16 . Has receive investigational drug within 4 week plan first dose study drug currently enrol investigational interventional study . 17 . Any condition , opinion investigator , would make participation best interest ( eg , compromise wellbeing ) subject could prevent , limit , confound protocolspecified assessment . 18 . Presence history cataract .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>9 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>